Safety, efficacy, and duration of effect of a new Botulinum Neurotoxin Type A preparation free of complexing proteins

被引：0

|

作者：

Wohlfarth, K

Mueller, C

机构：

来源：

MOVEMENT DISORDERS | 2005年 / 20卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P35

引用

收藏

页码：S11 / S11

页数：1

相关论文

共 50 条

[31] Efficacy and Safety of Repeated NT 201 (Botulinum Neurotoxin Type A Free from Complexing Proteins) Treatments for up to 89 Weeks in Upper Limb Post-Stroke Spasticity
Kanovsky, Petr
Pulte, Irena
Comes, Georg
Grafe, Susanne
NEUROLOGY, 2010, 74 (09) : A153 - A154
[32] Free of Complexing Proteins - Enough for Low Immunogenicity of Botulinum Neurotoxin Formulations? A Comparison of Excipients
Martin, Michael U.
Frevert, Juergen
TOXICON, 2024, 237 : 54 - 55
[33] SUSTAINED EFFICACY OF INCOBOTULINUMTOXIN-A (XEOMIN®; BOTULINUM NEUROTOXIN TYPE-A, FREE FROM COMPLEXING PROTEINS) IN LONG-TERM TREATMENT OF CERVICAL DYSTONIA
Dressler, D.
Kupsch, A.
Paus, S.
Seitzinger, A.
Gebhardt, B.
EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 482 - 482
[34] CLINICAL EFFICACY OF A NEW BOTULINUM TOXIN TYPE A FREE OF COMPLEXING PROTEINS IN THE TREATMENT OF REFRACTORY NEUROGENIC AND IDIOPATHIC DETRUSOR OVERACTIVITY
Yokoyama, Teruhiko
Ohira, Shin
Fujita, Masaichiro
Fukumoto, Kazuhiko
Fujii, Tomohiro
Jo, Yoshimasa
Miyaji, Yoshiyuki
Nagai, Atsushi
Oguma, Keiji
JOURNAL OF UROLOGY, 2012, 187 (04): : E478 - E478
[35] Effects of botulinum-neurotoxin-complexing proteins on lymphatic cells
Wang, L.
Sun, Y.
Singh, B. R.
TOXICON, 2013, 68 : 102 - 102
[36] Xeomin® is stable without refrigeration:: Complexing proteins are not required for stability of botulinum neurotoxin type A preparations
Grein, Swen
Mander, Gerd J.
Taylor, Harold V.
TOXICON, 2008, 51 : 13 - 13
[37] Are standard doses of incobotulinumtoxinA, botulinum neurotoxin A free from complexing proteins, not detected by the human immune system?
Hefter, H.
Hartmann, C.
Kahlen, U.
Moll, M.
TOXICON, 2013, 68 : 77 - 77
[38] BOTULINUM NEUROTOXIN TYPE A EXHIBITS A LINEAR CORRELATION BETWEEN DOSE, PEAK EFFICACY, AND DURATION OF EFFECT IN FUNCTIONAL ASSAYS
Nicholson, Greg S.
Canty, Dave
Brideau-Andersen, Amy D.
Broide, Ron S.
TOXICON, 2018, 156 : S83 - S84
[39] Botulinum neurotoxin type A exhibits a linear correlation between dose, peak efficacy, and duration of effect in functional assays
Nicholson, Greg S.
Canty, Dave
Brideau-Andersen, Amy
Broide, Ron S.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB176 - AB176
[40] Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX®) in healthy volunteers
Jost, WH
Kohl, A
Brinkmann, S
Comes, G
JOURNAL OF NEURAL TRANSMISSION, 2005, 112 (07) : 905 - 913

← 1 2 3 4 5 →